Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)

Avalo Therapeutics' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $38438.0 for Q4 2018.

For Q4 2018, Asset Writedowns and Impairment changed N/A year-over-year to $38438.0; the TTM value through Sep 2020 reached $38438.0, down 97.98%, while the annual FY2019 figure was $1.4 million, 23.73% down from the prior year.
Asset Writedowns and Impairment reached $38438.0 in Q4 2018 per AVTX's latest filing, down from $159687.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.7 million in Q2 2018 to a low of $38438.0 in Q4 2018.